These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33423780)

  • 21. Anal cancer treatment: current status and future perspectives.
    Ghosn M; Kourie HR; Abdayem P; Antoun J; Nasr D
    World J Gastroenterol; 2015 Feb; 21(8):2294-302. PubMed ID: 25741135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects.
    Pernot S; Terme M; Zaanan A; Tartour E; Weiss L; Taieb J
    Clin Res Hepatol Gastroenterol; 2014 Feb; 38(1):18-23. PubMed ID: 23932704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of human papillomavirus in anal squamous cell carcinoma.
    Ravenda PS; Magni E; Botteri E; Manzotti M; Barberis M; Vacirca D; Trovato CM; Dell'Acqua V; Leonardi MC; Sideri M; Fazio N; Zampino MG
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1033-8. PubMed ID: 25209946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy in Anal Cancer.
    Phuong L; Rajdev L
    Curr Oncol Rep; 2020 Jul; 22(9):94. PubMed ID: 32651760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
    Khawandanah M; Baxley A; Pant S
    J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal.
    Eng C; Jácome AA; Das P; Chang GJ; Rodriguez-Bigas M; Skibber JM; Wolff RA; Qiao W; Xing Y; Sethi S; Ohinata A; Crane CH
    Clin Colorectal Cancer; 2019 Dec; 18(4):301-306. PubMed ID: 31350201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New approaches in palliative systemic therapy of anal squamous cell carcinoma.
    Lohynská R; Pechačová Z
    Klin Onkol; 2022; 35(3):190-194. PubMed ID: 35760571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in advanced anal cancer: Is the beginning of a new era?
    Ciardiello D; Guerrera LP; Maiorano BA; Parente P; Latiano TP; Di Maio M; Ciardiello F; Troiani T; Martinelli E; Maiello E
    Cancer Treat Rev; 2022 Apr; 105():102373. PubMed ID: 35279535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
    Rödel F; Wieland U; Fraunholz I; Kitz J; Rave-Fränk M; Wolff HA; Weiss C; Wirtz R; Balermpas P; Fokas E; Rödel C
    Int J Cancer; 2015 Jan; 136(2):278-88. PubMed ID: 24839133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.
    Kim S; Boustani J; Vernerey D; Vendrely V; Evesque L; Francois E; Quero L; Ghiringhelli F; de la Fouchardière C; Dahan L; Bouché O; Chibaudel B; Hajbi FE; Vernet C; Rebucci-Peixoto M; Feuersinger A; Maritaz C; Borg C
    Front Oncol; 2022; 12():918499. PubMed ID: 36119522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
    Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal.
    Morris VK; Eng C
    J Natl Compr Canc Netw; 2018 Jul; 16(7):903-908. PubMed ID: 30006430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in the treatment of anal cancer: an overview of the latest investigational drugs.
    Yu J; Kim RD
    Expert Opin Investig Drugs; 2024 Feb; 33(2):145-157. PubMed ID: 38275174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic Anal Cancer and Novel Agents.
    Morris V; Eng C
    Surg Oncol Clin N Am; 2017 Jan; 26(1):133-142. PubMed ID: 27889032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma.
    Soares PC; Abdelhay ES; Thuler LCS; Soares BM; Demachki S; Ferro GVR; Assumpção PP; Lamarão LM; Ribeiro Pinto LF; Burbano RMR
    BMC Gastroenterol; 2018 Feb; 18(1):30. PubMed ID: 29466950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
    James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
    Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor inhibition in metastatic anal cancer.
    Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
    Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis.
    Pala L; De Pas T; Stucchi E; Catania C; Cocorocchio E; Zampino MG; Rossi G; Zattarin E; Di Muzio A; Laszlo D; Stucchi S; Conforti F
    Semin Oncol; 2023 Dec; 50(6):140-143. PubMed ID: 38065801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.